- Home
- BRZE vs ATAI Comparison
BRZE vs ATAI Comparison
Compare BRZE & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRZE | ATAI |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BRZE | ATAI |
|---|---|---|
| Price | $23.98 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 8 |
| Target Price | ★ $37.88 | $15.88 |
| AVG Volume (30 Days) | 2.0M | ★ 17.7M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $738,182,000.00 | $4,089,000.00 |
| Revenue This Year | $22.69 | N/A |
| Revenue Next Year | $16.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 24.40 | ★ 1227.60 |
| 52 Week Low | $15.26 | $3.27 |
| 52 Week High | $37.33 | $7.22 |
Technical Indicators
Market Signals| Indicator | BRZE | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 73.17 |
| Support Level | $22.09 | $3.47 |
| Resistance Level | $24.53 | N/A |
| Average True Range (ATR) | 1.58 | 0.23 |
| MACD | -0.34 | 0.11 |
| Stochastic Oscillator | 55.86 | 98.13 |
Price Performance
Historical ComparisonAbout BRZE Braze Inc.
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates the majority of its revenue from the United States.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.